4.6 Article

Molecular markers of telomere dysfunction and senescence are common findings in the usual interstitial pneumonia pattern of lung fibrosis

Journal

HISTOPATHOLOGY
Volume 79, Issue 1, Pages 67-76

Publisher

WILEY
DOI: 10.1111/his.14334

Keywords

alveolar type II cell; hypersensitivity pneumonitis; interstitial lung disease; pulmonary fibrosis; rheumatoid arthritis; scleroderma; senescence; telomere

Funding

  1. NIH [HL139897, HL108794, HL138131]
  2. National Center for Advancing Translational Science, NIH [UCSF-CTI KL2TR000143]
  3. Nina Ireland Program in Lung Health
  4. Scleroderma Research Foundation
  5. Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Ask authors/readers for more resources

The study found that molecular markers of telomere dysfunction and senescence are pathologically expressed in both IPF and non-IPF UIP lungs, suggesting that common molecular drivers may contribute to the pathogenesis of UIP-associated pulmonary fibrosis, regardless of the clinical diagnosis.
Aims Idiopathic pulmonary fibrosis (IPF) is a genetically mediated, age-associated, progressive form of pulmonary fibrosis characterised pathologically by a usual interstitial pneumonia (UIP) pattern of fibrosis. The UIP pattern is also found in pulmonary fibrosis attributable to clinical diagnoses other than IPF (non-IPF UIP), whose clinical course is similarly poor, suggesting common molecular drivers. This study investigates whether IPF and non-IPF UIP lungs similarly express markers of telomere dysfunction and senescence. Methods and results To test whether patients with IPF and non-IPF UIP share molecular drivers, lung tissues from 169 IPF patients and 57 non-IPF UIP patients were histopathologically and molecularly compared. Histopathological changes in both IPF and non-IPF UIP patients included temporal heterogeneity, microscopic honeycombing, fibroblast foci, and dense collagen fibrosis. Non-IPF UIP lungs were more likely to have lymphocytic infiltration, non-caseating granulomas, airway-centred inflammation, or small airways disease. Telomeres were shorter in alveolar type II (AECII) cells of both IPF and non-IPF UIP lungs than in those of age-similar, unused donor, controls. Levels of molecular markers of senescence (p16 and p21) were elevated in lysates of IPF and non-IPF UIP lungs. Immunostaining localised expression of these proteins to AECII cells. The mucin 5B (MUC5B) gene promoter variant minor allele frequency was similar between IPF and non-IPF UIP patients, and MUC5B expression was similar in IPF and non-IPF UIP lungs. Conclusions Molecular markers of telomere dysfunction and senescence are pathologically expressed in both IPF and non-IPF UIP lungs. These findings suggest that common molecular drivers may contribute to the pathogenesis of UIP-associated pulmonary fibrosis, regardless of the clinical diagnosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Respiratory System

Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis

Haruhiko Furusawa, Anna L. Peljto, Avram D. Walts, Jonathan Cardwell, Philip L. Molyneaux, Joyce S. Lee, Evans R. Fernandez Perez, Paul J. Wolters, Ivana Yang, David A. Schwartz

Summary: A study found that a subset of patients with hypersensitivity pneumonitis (HP) develop lung fibrosis that is clinically similar to idiopathic pulmonary fibrosis (IPF). The study also identified certain genetic variants that were significantly associated with fibrotic HP, indicating a shared etiology and pathogenesis between fibrotic HP and IPF.

THORAX (2022)

Article Critical Care Medicine

Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis

Willis S. Bowman, Chad A. Newton, Angela L. Linderholm, Megan L. Neely, Janelle Vu Pugashetti, Bhavika Kaul, Vivian Vo, Gabrielle A. Echt, William Leon, Rupal J. Shah, Yong Huang, Christine Kim Garcia, Paul J. Wolters, Justin M. Oldham

Summary: This study aims to identify plasma biomarkers of progressive fibrosing interstitial lung disease (ILD) and develop a proteomic signature to predict this phenotype. The study identified 17 plasma biomarkers associated with progressive fibrosing ILD and developed a proteomic signature that can differentiate between high-risk and low-risk patients in clinical trials.

LANCET RESPIRATORY MEDICINE (2022)

Article Critical Care Medicine

Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease Data From the Pulmonary Fibrosis Foundation Patient Registry

Janet Lee, Emily White, Elizabeth Freiheit, Mary Beth Scholand, Mary E. Strek, Anna J. Podolanczuk, Nina M. Patel

Summary: Cough-specific quality of life assessment can predict disease progression, respiratory hospitalizations, lung transplantation, and death among patients with interstitial lung disease.

CHEST (2022)

Article Biology

Acquisition of cellular properties during alveolar formation requires differential activity and distribution of mitochondria

Kuan Zhang, Erica Yao, Biao Chen, Ethan Chuang, Julia Wong, Robert Seed, Stephen L. Nishimura, Paul J. Wolters, Pao-Tien Chuang, Melanie Koenigshoff

Summary: This study revealed the crucial role of mitochondria in the formation of alveoli in mice, affecting cellular functions and key steps of alveologenesis. Mitochondrial regulation enables lung epithelial cells to secrete ligands influencing myofibroblast proliferation and movement, while also impacting myofibroblast contraction and migration.

ELIFE (2022)

Letter Critical Care Medicine

Differences in Patient Outcomes across the Pulmonary Fibrosis Foundation Care Center Network

Ryan D. Boente, Emily N. White, Caitlin M. Baxter, Jessica E. Shore, Harold R. Collard, Joyce S. Lee

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Medicine, Research & Experimental

Real-World Clinical Outcomes Based on Body Mass Index and Annualized Weight Change in Patients with Idiopathic Pulmonary Fibrosis

Joyce S. Lee, Adam Martin-Schwarze, Elizabeth Freiheit, Ben Trzaskoma, Cindy Burg

Summary: This study examined the relationship between clinical outcomes and body mass index (BMI) and weight change in patients with idiopathic pulmonary fibrosis (IPF). The results showed that patients with a low BMI or weight loss over 24 months may have worse clinical outcomes, but the causation for these relationships is unknown.

ADVANCES IN THERAPY (2023)

Article Critical Care Medicine

Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants

Anna L. Peljto, Rachel Z. Blumhagen, Avram D. Walts, Jonathan Cardwell, Julia Powers, Tamera J. Corte, Joanne L. Dickinson, Ian Glaspole, Yuben P. Moodley, Martina Koziar Vasakova, Elisabeth Bendstrup, Jesper R. Davidsen, Raphael Borie, Bruno Crestani, Philippe Dieude, Francesco Bonella, Ulrich Costabel, Gunnar Gudmundsson, Seamas C. Donnelly, Jim Egan, Michael T. Henry, Michael P. Keane, Marcus P. Kennedy, Cormac McCarthy, Aoife N. McElroy, Joshua A. Olaniyi, Katherine M. A. O'Reilly, Luca Richeldi, Paolo M. Leone, Venerino Poletti, Francesco Puppo, Sara Tomassetti, Valentina Luzzi, Nurdan Kokturk, Nesrin Mogulkoc, Christine A. Fiddler, Nikhil Hirani, R. Gisli Jenkins, Toby M. Maher, Philip L. Molyneaux, Helen Parfrey, Rebecca Braybrooke, Timothy S. Blackwell, Peter D. Jackson, Steven D. Nathan, Mary K. Porteous, Kevin K. Brown, Jason D. Christie, Harold R. Collard, Oliver Eickelberg, Elena E. Foster, Kevin F. Gibson, Marilyn Glassberg, Daniel J. Kass, Jonathan A. Kropski, David Lederer, Angela L. Linderholm, Jim Loyd, Susan K. Mathai, Sydney B. Montesi, Imre Noth, Justin M. Oldham, Amy J. Palmisciano, Cristina A. Reichner, Mauricio Rojas, Jesse Roman, Neil Schluger, Barry S. Shea, Jeffrey J. Swigris, Paul J. Wolters, Yingze Zhang, Cecilia M. A. Prele, Juan I. Enghelmayer, Maria Otaola, Christopher J. Ryerson, Mauricio Salinas, Martina Sterclova, Tewodros H. Gebremariam, Marjukka Myllarniemi, Roberto G. Carbone, Haruhiko Furusawa, Masaki Hirose, Yoshikazu Inoue, Yasunari Miyazaki, Ken Ohta, Shin Ohta, Tsukasa Okamoto, Dong Soon Kim, Annie Pardo, Moises Selman, Alvaro U. Aranda, Moo Suk Park, Jong Sun Park, Jin Woo Song, Maria Molina-Molina, Lurdes Planas-Cerezales, Gunilla Westergren-Thorsson, Albert V. Smith, Ani W. Manichaikul, John S. Kim, Stephen S. Rich, Elizabeth C. Oelsner, R. Graham Barr, Jerome I. Rotter, Josee Dupuis, George O'Connor, Ramachandran S. Vasan, Michael H. Cho, Edwin K. Silverman, Marvin I. Schwarz, Mark P. Steele, Joyce S. Lee, Ivana V. Yang, Tasha E. Fingerlin, David A. Schwartz

Summary: This study investigated the role of rare variants, genome-wide, on the risk of idiopathic pulmonary fibrosis (IPF) using whole-genome sequencing. The results showed that rare variants within the TERT and RTEL1 genes were significantly associated with IPF, along with well-established common variants. Therefore, including TERT, RTEL1, common variants, and environmental risk factors in risk profiling and IPF therapy development is likely to have the largest impact on this complex disease.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Letter Critical Care Medicine

Identification of a Genetic Susceptibility Locus for Idiopathic Pulmonary Fibrosis in the 16p Subtelomere Using Whole-Genome Sequencing

Lauren J. Donoghue, Amy D. Stockwell, Margaret Neighbors, Rebecca X. Sheng, Ramanandan Prabhakaran, Paul J. Wolters, Lisa H. Lancaster, Jonathan A. Kropski, Timothy S. Blackwell, Mark I. McCarthy, Brian L. Yaspan

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Respiratory System

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone

Hsiao-Yen Ma, Jason A. Vander Heiden, Salil Uttarwar, Ying Xi, Elsa-Noah N'Diaye, Ryan LaCanna, Patrick Caplazi, Sarah Gierke, John Moffat, Paul J. Wolters, Ning Ding

Summary: This study found that MRTF signaling is activated in myofibroblasts accumulated in IPF lungs. PFD inhibits MRTF activation in primary human lung fibroblasts at clinically achievable concentrations. These findings suggest that MRTF signaling may be a direct target for PFD and that its anti-fibrotic effects may be due to MRTF inhibition in lung fibroblasts.

EUROPEAN RESPIRATORY JOURNAL (2023)

Article Critical Care Medicine

PCSK6 and Survival in Idiopathic Pulmonary Fibrosis

Justin M. Oldham, Richard J. Allen, Jose M. Lorenzo-Salazar, Philip L. Molyneaux, Shwu-Fan Ma, Chitra Joseph, John S. Kim, Beatriz Guillen-Guio, Tamara Hernandez-Beeftink, Jonathan A. Kropski, Yong Huang, Cathryn T. Lee, Ayodeji Adegunsoye, Janelle Vu Pugashetti, Angela L. Linderholm, Vivian Vo, Mary E. Strek, Jonathan Jou, Adrian Munoz-Barrera, Luis A. Rubio-Rodriguez, Richard Hubbard, Nik Hirani, Moira K. B. Whyte, Simon Hart, Andrew G. Nicholson, Lisa Lancaster, Helen Parfrey, Doris Rassl, William Wallace, Eleanor Valenzi, Yingze Zhang, Josyf Mychaleckyj, Amy Stockwell, Naftali Kaminski, Paul J. Wolters, Maria Molina-Molina, Nicholas E. Banovich, William A. Fahy, Fernando J. Martinez, Ian P. Hall, Martin D. Tobin, Toby M. Maher, Timothy S. Blackwell, Brian L. Yaspan, R. Gisli Jenkins, Carlos Flores, Louise V. Wain, Imre Noth

Summary: This study conducted a staged genome-wide association study to identify and validate molecular determinants of survival in idiopathic pulmonary fibrosis (IPF). Four novel variants associated with IPF survival were identified, including one within the PCSK6 gene that reached genome-wide significance. Downstream analyses suggested that PCSK6 protein may play an important role in IPF progression.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Immunology

Dysregulated lung stroma drives emphysema exacerbation by potentiating resident lymphocytes to suppress an epithelial stem cell reservoir

Chaoqun Wang, Ben Hyams, Nancy C. Allen, Kelly Cautivo, Kiara Monahan, Minqi Zhou, Madelene W. Dahlgren, Carlos O. Lizama, Michael Matthay, Paul Wolters, Ari B. Molofsky, Tien Peng

Summary: Abnormal tissue-immune interactions are characteristic of chronic lung diseases. In emphysema, the expansion of tissue-resident lymphocytes (TRLs) was observed. A stromal niche expressing the disease-variant gene Hhip was identified, and its deletion led to the expansion of TRLs through the hedgehog-IL-7 axis. Expanded TRLs suppressed alveolar stem cell growth through IFNg, and a subset of human alveolar stem cells sensitive to IFNg was lost in emphysema.

IMMUNITY (2023)

Article Multidisciplinary Sciences

Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts

Ayodeji Adegunsoye, Chad A. Newton, Justin M. Oldham, Brett Ley, Cathryn T. Lee, Angela L. Linderholm, Jonathan H. Chung, Nicole Garcia, Da Zhang, Rekha Vij, Robert Guzy, Renea Jablonski, Remzi Bag, Rebecca S. Voogt, Shwu-Fan Ma, Anne I. Sperling, Ganesh Raghu, Fernando J. Martinez, Mary E. Strek, Paul J. Wolters, Christine Kim Garcia, Brandon L. Pierce, Imre Noth

Summary: This study investigated the association between leukocyte telomere length (LTL) and age and mortality in racially diverse patients with pulmonary fibrosis (PF). The study found that LTL shortened with increasing age, and this association was even stronger in PF patients. In all racial groups, LTL below the median predicted worse mortality.

NATURE COMMUNICATIONS (2023)

Article Medicine, General & Internal

Evaluation of Pulmonary Fibrosis Outcomes by Race and Ethnicity in US Adults

Ayodeji Adegunsoye, Elizabeth Freiheit, Emily N. White, Bhavika Kaul, Chad A. Newton, Justin M. Oldham, Cathryn T. Lee, Jonathan Chung, Nicole Garcia, Sahand Ghodrati, Rekha Vij, Renea Jablonski, Kevin R. Flaherty, Paul J. Wolters, Christine Kim Garcia, Mary E. Strek

Summary: This cohort study examines the age differences and survival patterns in pulmonary fibrosis (PF)-related outcomes among Hispanic, non-Hispanic Black, and non-Hispanic White participants. The study found racial and ethnic disparities, particularly among Black patients, in PF-related outcomes, including earlier onset of death.

JAMA NETWORK OPEN (2023)

Article Respiratory System

Interstitial Lung Disease in Veterans: Leveraging Big Data to Bridge Evidence and Practice Gaps

Bhavika Kaul, Laura A. Petersen, Ivan O. Rosas, Joyce S. Lee, Fernando J. Martinez, Venkata D. Bandi, Drew A. Helmer, Paul J. Wolters, Harold R. Collard, Mary A. Whooley

ANNALS OF THE AMERICAN THORACIC SOCIETY (2023)

Review Medicine, General & Internal

Diffuse lung involvement in rheumatoid arthritis: a respiratory physician's perspective

Hui Huang, Ruxuan Chen, Chi Shao, Zuojun Xu, Paul J. Wolters

Summary: Respiratory complications are common in rheumatoid arthritis (RA), with interstitial lung disease being the most common manifestation. Recent progress has been made in understanding the management and progression of RA-associated interstitial lung disease (RA-ILD) and other respiratory diseases in RA. In this review, we will update the diagnosis and treatment of RA-associated ILD, methotrexate-associated lung disease, and the complication of Pneumocystis jiroveci pneumonia in RA from a chest physicians' perspective.

CHINESE MEDICAL JOURNAL (2023)

No Data Available